Seeking Alpha

Celgene (CELG) says Phase 3 studies of Abraxane, a treatment for advanced pancreatic cancer, met...

Celgene (CELG) says Phase 3 studies of Abraxane, a treatment for advanced pancreatic cancer, met its primary endpoint of overall survival. Based on the results, the company plans to submit applications for registration in the U.S., Europe and other markets.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs